S
Sorafenib
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Standard Drug List
Active ingredient: Sorafenib
General information
Subsidy Information and Financing Scheme
Drug Guidance for Subsidy
04/01/2022 Lenvatinib and sorafenib for treating advanced hepatocellular carcinoma
The Ministry of Health’s Drug Advisory Committee has recommended:
Sorafenib 200 mg tablet; and
Lenvatinib 4 mg and 10 mg capsules
for treating advanced unresectable hepatocellular carcinoma in patients with adequate liver function as assessed by the Child-Pugh scoring system.
Subsidy status
[R] Sorafenib 200 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) and lenvatinib 4 mg and 10 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication when used according to HSA-recommended dosing regimens.
[R] SDL subsidy for sorafenib will be implemented from 4 January 2022, while MAF assistance for lenvatinib will be implemented from 1 September 2022.
Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.
04/01/2022 Lenvatinib and sorafenib for treating differentiated thyroid cancer
The Ministry of Health’s Drug Advisory Committee has recommended:
Sorafenib 200 mg tablet; and
Lenvatinib 4 mg and 10 mg capsules
for treating locally advanced or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
Subsidy status
[R] Sorafenib 200 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication with effect from 4 January 2022.
[R] Lenvatinib 4 mg and 10 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication with effect from 1 September 2022.
Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Tablet 200 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.